New pharmacological approaches to therapy of NIDDM

Rubin Bressler, David G Johnson

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Currently available pharmacological agents have not been completely successful in restoring euglycemia in the non-insulin-dependent diabetes mellitus (NIDDM) patient. Several new approaches to the therapy of NIDDM have been formulated in recent years and are in various stages of laboratory or pharmaceutical development. Several of these agents are discussed in this article under categories relating to their mechanisms of lowering blood glucose: 1) inhibition of the release or action of counterregulatory hormones; 2) inhibition of postprandial glucose rise; 3) sensitization of tissues to insulin's actions; and 4) inhibition of gluconeogenesis, including inhibition of the long-chain acyl-CoA-carnitine acyltransferase I, the long-chain acylcarnitine translocase, and pyruvate carboxylase.

Original languageEnglish (US)
JournalDiabetes Care
Volume15
Issue number6
StatePublished - Jun 1992

Fingerprint

Type 2 Diabetes Mellitus
Carnitine Acyltransferases
Pharmacology
Pyruvate Carboxylase
Carnitine O-Palmitoyltransferase
Acyl Coenzyme A
Gluconeogenesis
Blood Glucose
Hormones
Glucose
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

New pharmacological approaches to therapy of NIDDM. / Bressler, Rubin; Johnson, David G.

In: Diabetes Care, Vol. 15, No. 6, 06.1992.

Research output: Contribution to journalArticle

@article{6bbada877baa401f96b5af2958ede88d,
title = "New pharmacological approaches to therapy of NIDDM",
abstract = "Currently available pharmacological agents have not been completely successful in restoring euglycemia in the non-insulin-dependent diabetes mellitus (NIDDM) patient. Several new approaches to the therapy of NIDDM have been formulated in recent years and are in various stages of laboratory or pharmaceutical development. Several of these agents are discussed in this article under categories relating to their mechanisms of lowering blood glucose: 1) inhibition of the release or action of counterregulatory hormones; 2) inhibition of postprandial glucose rise; 3) sensitization of tissues to insulin's actions; and 4) inhibition of gluconeogenesis, including inhibition of the long-chain acyl-CoA-carnitine acyltransferase I, the long-chain acylcarnitine translocase, and pyruvate carboxylase.",
author = "Rubin Bressler and Johnson, {David G}",
year = "1992",
month = "6",
language = "English (US)",
volume = "15",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - New pharmacological approaches to therapy of NIDDM

AU - Bressler, Rubin

AU - Johnson, David G

PY - 1992/6

Y1 - 1992/6

N2 - Currently available pharmacological agents have not been completely successful in restoring euglycemia in the non-insulin-dependent diabetes mellitus (NIDDM) patient. Several new approaches to the therapy of NIDDM have been formulated in recent years and are in various stages of laboratory or pharmaceutical development. Several of these agents are discussed in this article under categories relating to their mechanisms of lowering blood glucose: 1) inhibition of the release or action of counterregulatory hormones; 2) inhibition of postprandial glucose rise; 3) sensitization of tissues to insulin's actions; and 4) inhibition of gluconeogenesis, including inhibition of the long-chain acyl-CoA-carnitine acyltransferase I, the long-chain acylcarnitine translocase, and pyruvate carboxylase.

AB - Currently available pharmacological agents have not been completely successful in restoring euglycemia in the non-insulin-dependent diabetes mellitus (NIDDM) patient. Several new approaches to the therapy of NIDDM have been formulated in recent years and are in various stages of laboratory or pharmaceutical development. Several of these agents are discussed in this article under categories relating to their mechanisms of lowering blood glucose: 1) inhibition of the release or action of counterregulatory hormones; 2) inhibition of postprandial glucose rise; 3) sensitization of tissues to insulin's actions; and 4) inhibition of gluconeogenesis, including inhibition of the long-chain acyl-CoA-carnitine acyltransferase I, the long-chain acylcarnitine translocase, and pyruvate carboxylase.

UR - http://www.scopus.com/inward/record.url?scp=0026633018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026633018&partnerID=8YFLogxK

M3 - Article

C2 - 1600838

AN - SCOPUS:0026633018

VL - 15

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -